[go: up one dir, main page]

AR038369A1 - Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto - Google Patents

Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto

Info

Publication number
AR038369A1
AR038369A1 ARP030100268A ARP030100268A AR038369A1 AR 038369 A1 AR038369 A1 AR 038369A1 AR P030100268 A ARP030100268 A AR P030100268A AR P030100268 A ARP030100268 A AR P030100268A AR 038369 A1 AR038369 A1 AR 038369A1
Authority
AR
Argentina
Prior art keywords
trifluoromethyl
drug
microns
benzyl
drops
Prior art date
Application number
ARP030100268A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR038369A1 publication Critical patent/AR038369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Glanulating (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

Dispersiones sólidas amorfas homogéneas de fármacos en polímeros mejoradores de la concentración se preparan en tamanos de partícula más grandes adecuados con mínimo contenido de fines, utilizando un atomizador y condiciones de procedimiento capaces de producir gotas que tienen un diámetro medio de al menos 50 micrones y un D10 de al menos 10 micrones. Reivindicación 1: Un procedimiento para producir una composición farmacéutica, caracterizado porque comprende las etapas de: (a) formar una disolución de alimentación que comprende un fármaco, un polímero mejorador de la concentración y un disolvente; (b) dirigir dicha disolución de alimentación hacia un aparato de secado por pulverización que comprende una cámara de secado, medios de atomización para atomizar en gotas dicha disolución de alimentación en dicha cámara de secado, una fuente de gas de secado calentando para secar dichas gotas y medios de recogida del producto secado; (c) atomizar en gotas dicha disolución de alimentación en dicha cámara de secado mediante dichos medios de atomización, teniendo dichas gotas un diámetro medio de al menos 50 micrones y un D10 de al menos 10 micrones; (d) poner en contacto dichas gotas con dicho gas de secado calentado para preparar materiales en partículas de una dispersión sólida amorfa de dicho fármaco y dicho polímero mejorador de la concentración; y (e) recoger dichos materiales en partículas: en el que dicho polímero mejorador de la concentración está presente en dicha disolución en una cantidad suficiente, de manera que dicha dispersión sólida amorfa proporciona una mejora de la concentración de dicho fármaco en un medio de utilización con respecto a una composición testigo que consiste esencialmente en una cantidad equivalente de dicho fármaco solo. Reivindicación 9: El procedimiento según la reivindicación 1, caracterizado porque dicho fármaco se elige del grupo que consta [R-(R*S*)]-5-cloro-N-2-hidroxi-3-{metoximetilamino}-3-oxo-1-(fenilmetil)propil-1H-indol-2-carboxamida, [(1S)-bencil-(2R)-hidroxi-3-((3R,4S)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del ácido 5-cloro-1H-indol-2-carboxílico, éster isopropílico del ácido [2R,4S]-4-[acetil(3,5-bis-trifluorometil-bencil)-amino]-2-etil-6-trifluorometil-3,4-dihidro-2H-quinolin-1-carboxílico, éster etílico del ácido [2R,4S]-4-(3,5-bis-trifluorometil-bencil)-metoxicarbonil-amino]-2-etil-6-trifluorometil-3,4-dihidro-2H-quinolin-1-carboxílico y éster isopropílico del ácido [2R,4S]-4-[(3,5-bis-trifluorometil-bencil)-metoxicarbonil-amino]-2-etil-6-trifluorometil-3,4-dihidro-2H-quinolin-1-carboxílico.
ARP030100268A 2002-02-01 2003-01-30 Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto AR038369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35398602P 2002-02-01 2002-02-01

Publications (1)

Publication Number Publication Date
AR038369A1 true AR038369A1 (es) 2005-01-12

Family

ID=27663274

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100268A AR038369A1 (es) 2002-02-01 2003-01-30 Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto

Country Status (20)

Country Link
US (1) US7780988B2 (es)
EP (1) EP1469830A2 (es)
JP (1) JP2005523260A (es)
KR (1) KR100758045B1 (es)
CN (1) CN1787808A (es)
AR (1) AR038369A1 (es)
AU (1) AU2003239463B2 (es)
BR (1) BR0307515A (es)
CA (1) CA2474958A1 (es)
GT (1) GT200300024A (es)
MX (1) MXPA04007435A (es)
PA (1) PA8565401A1 (es)
PE (1) PE20030804A1 (es)
PL (1) PL371593A1 (es)
RS (1) RS67304A (es)
RU (1) RU2288703C2 (es)
TW (1) TW200404576A (es)
UY (1) UY27645A1 (es)
WO (1) WO2003063821A2 (es)
ZA (1) ZA200405971B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN1787808A (zh) 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
CA2472028C (en) 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2560984A1 (en) 2004-06-01 2005-12-15 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for preparation of amorphous form of a drug
DK2502911T3 (en) 2004-06-24 2017-06-06 Vertex Pharma Modulators of ATP-binding cassette transporters
EP1817315A1 (en) 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Processes for producing crystalline macrolides
US9265731B2 (en) 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN101272769B (zh) 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
CN101304970A (zh) * 2005-12-21 2008-11-12 卫材R&D管理有限公司 1，2-二氢吡啶化合物的无定形物
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
BRPI0707584A2 (pt) 2006-02-09 2011-05-10 Merck & Co Inc composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
MX2008015686A (es) 2006-06-06 2009-01-12 Tibotec Pharm Ltd Procedimiento para preparar formulaciones secadas por aspersion de etravirina.
US8834929B2 (en) 2006-07-21 2014-09-16 Bend Research, Inc. Drying of drug-containing particles
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
RU2543714C2 (ru) 2009-03-20 2015-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
EP2813220A3 (en) 2010-04-09 2015-06-17 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
UA108886C2 (ru) 2010-06-09 2015-06-25 Еббві Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
AU2012204462A1 (en) 2011-01-05 2013-07-11 Hospira, Inc. Spray drying vancomycin
TWI520732B (zh) * 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
PT106063B (pt) * 2011-12-19 2017-05-30 Inst Superior Tecnico Minociclina cristalina termorresistente produzida por recristalização com dióxido de carbono
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
RU2699358C2 (ru) 2012-05-31 2019-09-05 Мерк Шарп И Доум Корп. Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
CN105358535B (zh) * 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
BR112014011938B1 (pt) 2013-01-31 2021-03-16 Gilead Pharmasset Llc composição farmacêutica na forma de um comprimido com uma combinação de dose fixa de dois compostos antivirais, forma de dosagem farmacêutica compreendendo a referida composição e uso da referida composição
WO2014121137A2 (en) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
CN103694903B (zh) * 2013-12-02 2015-07-01 南通瑞普埃尔生物工程有限公司 一种瞬干胶粘剂及其制备方法
JP6505705B2 (ja) * 2013-12-05 2019-04-24 アルライズ バイオシステムズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用製剤の製造方法
JP6649378B2 (ja) * 2014-07-25 2020-02-19 ローラン・ファーマシューティカルズ フェンレチニドの固体経口処方物
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
WO2016067132A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
WO2016090105A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
SG11201704267VA (en) * 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
RU2585023C1 (ru) * 2014-12-18 2016-05-27 Общество с ограниченной ответственностью "Нанолек" Способ гранулирования
EP3307246A1 (en) 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
TW201818933A (zh) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
BR112021001170A2 (pt) 2018-07-30 2021-04-27 Chugai Seiyaku Kabushiki Kaisha dispersão sólida de derivado de hidantoína
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
JP2022554352A (ja) * 2019-11-06 2022-12-28 マンカインド コーポレイション クロファジミンの組成物、それを含む組合せ、その調製プロセス、それを含む使用及び処置方法
WO2021138485A1 (en) 2019-12-30 2021-07-08 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
KR20230097021A (ko) 2020-09-29 2023-06-30 선전 파마신 컴퍼니 리미티드 약학 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1131242A (en) 1965-02-18 1968-10-23 Gen Foods Ltd Improvements in or relating to spray-drying apparatus
DE2201111A1 (de) 1971-01-19 1972-07-27 Niro Atomizer As Zerstaeubungstrocknungsvorrichtung zur Herstellung von Pulver,z.B. Milchpulver
IT1025765B (it) 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
DE2741196A1 (de) * 1977-09-13 1979-03-15 Bayer Ag Verfahren zur herstellung von perlpolymeren
US4187617A (en) 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4702799A (en) 1985-09-03 1987-10-27 Nestec S.A. Dryer and drying method
US6068859A (en) 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
EP1027887B1 (en) 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CN1787808A (zh) 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
CA2472028C (en) * 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Also Published As

Publication number Publication date
AU2003239463B2 (en) 2007-10-18
EP1469830A2 (en) 2004-10-27
BR0307515A (pt) 2004-12-07
MXPA04007435A (es) 2004-10-11
KR100758045B1 (ko) 2007-09-11
US7780988B2 (en) 2010-08-24
JP2005523260A (ja) 2005-08-04
PA8565401A1 (es) 2003-12-10
RU2004123639A (ru) 2005-04-20
ZA200405971B (en) 2006-05-31
WO2003063821A2 (en) 2003-08-07
GT200300024A (es) 2003-09-22
CN1787808A (zh) 2006-06-14
TW200404576A (en) 2004-04-01
PE20030804A1 (es) 2003-09-19
PL371593A1 (en) 2005-06-27
US20030185893A1 (en) 2003-10-02
UY27645A1 (es) 2003-09-30
RU2288703C2 (ru) 2006-12-10
RS67304A (en) 2006-10-27
WO2003063821A3 (en) 2003-11-13
CA2474958A1 (en) 2003-08-07
KR20040083491A (ko) 2004-10-02

Similar Documents

Publication Publication Date Title
AR038369A1 (es) Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto
Sultanova et al. Controlled release of a hydrophilic drug from coaxially electrospun polycaprolactone nanofibers
Yuan et al. Preparation of self-assembled nanoparticles of ε-polylysine-sodium alginate: a sustained-release carrier for antigen delivery
Wenk et al. Silk fibroin spheres as a platform for controlled drug delivery
Kolakovic et al. Spray-dried nanofibrillar cellulose microparticles for sustained drug release
Freitas et al. Ultrasonic atomisation into reduced pressure atmosphere—envisaging aseptic spray-drying for microencapsulation
RU2278659C9 (ru) Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
JP5302197B2 (ja) 両親媒性コポリマーおよび調節放出の有効成分を基にした微小粒子、ならびにこれらを含む医薬製剤
Zheng et al. Post-electrospinning “triclick” functionalization of degradable polymer nanofibers
IL248161B (en) Improved spray drying process for production of powders with enhanced properties
CN1088092A (zh) 微颗粒制剂及其生产方法
Wen et al. Preparation and characterization of protein-loaded electrospun fiber mat and its release kinetics
Yu et al. Liposomes self-assembled from electrosprayed composite microparticles
US20230094393A1 (en) Peptide particles and methods of formation
CN102083419A (zh) 包含表面被覆了的微粒的医药组合物
MXPA06001418A (es) Procedimientos de secado por pulverizacion para la formacion de dispersiones solidas amorfas de farmacos y polimeros.
Feng et al. Polymeric nanospheres fabricated with natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol®)
CN102198102A (zh) 一种载药微球的制备方法
Soares et al. A novel globular protein electrospun fiber mat with the addition of polysilsesquioxane
Elkordy et al. Dissolution of ibuprofen from spray dried and spray chilled particles
US20130035279A1 (en) Method and a system for producing thermolabile nanoparticles with controlled properties and nanoparticles matrices made thereby
CN107847436A (zh) 凝胶组合物和凝胶组合物的制造方法
Zorec et al. Particle properties and drug metastable solubility of simvastatin containing PVP matrix particles prepared by electrospraying technique
CN106562931B (zh) 一种短链脂肪酸囊泡的制备方法
Desai et al. Solubility enhancement of ritonavir by hot melt extrusion

Legal Events

Date Code Title Description
FB Suspension of granting procedure